RSS
WX

Rosenblum Silverman Sutton’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Rosenblum Silverman Sutton’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-82,610
Closed -$3.57M – 68
2015
Q3 		$3.57M Sell
82,610
-5,150
-6% -$217K 1.7% 24
2015
Q2 		$3.71M Buy
+87,760
New +$3.7M 1.48% 28
2014
Q4 		$2.95M Sell
87,560
-900
-1% -$31.8K 1.27% 30
2014
Q3 		$3.1M Sell
88,460
-1,350
-2% -$46.3K 1.39% 30
2014
Q2 		$2.95M Sell
89,810
-1,650
-2% -$56.5K 1.38% 29
2014
Q1 		$3.37M Buy
91,460
+900
+1% +$33K 1.6% 24
2013
Q4 		$3.48M Sell
90,560
-250
-0.3% -$7.89K 1.64% 23
2013
Q3 		$2.49M Buy
+90,810
New +$2.15M 1.33% 35

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Rosenblum Silverman Sutton's WX Position: Q4 2015 in Review

Rosenblum Silverman Sutton sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 82,610 shares — an estimated $3.57M sold.

Rosenblum Silverman Sutton first reported a position in WX in Q3 2013 and held it in 8 quarters. The position peaked at $3.71M in Q2 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Rosenblum Silverman Sutton reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Rosenblum Silverman Sutton sold 82,610 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $3.57M.
  • Rosenblum Silverman Sutton first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 8 quarters.
  • Rosenblum Silverman Sutton's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $3.71M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Rosenblum Silverman Sutton's 13F filing for Q4 2015, filed 16 Feb 2016.